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experience, including preference for GLM and the auto-injector over previousmed-
ication and injection device.
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ASSOCIATION BETWEEN RESTRICTIONS ON CELECOXIB USE AND HEALTH
CARE UTILIZATION AND COSTS IN MEDICARE BENEFICIARIES WITH ARTHRITIS
Durden E1, Maiese BA2, Essex MN3, Cappelleri JC4, Joshi AV3
1Thomson Reuters, Austin, TX, USA, 2Thomson Reuters, Cambridge, PA, USA, 3Pfizer, Inc., New
York, NY, USA, 4Pfizer, Inc., Groton, CT, USA
OBJECTIVES: To examine the association between access restrictions on celecoxib
use and healthcare costs in Medicare patients with arthritis.METHODS: Enrollees
diagnosed with osteoarthritis (OA) or rheumatoid arthritis (RA) between January 1,
2008 and December 31, 2010 (index date) and at least 24 months of continuous
health plan enrollment (I-year pre- and post-index date) were identified from 12
health plans with and without access restrictions to celecoxib in the MarketScan®
Medicare Supplemental and Coordination of Benefits Database. Utilization of celecoxib,
all-cause, gastrointestinal (GI) event-related, and OA/RA-related healthcare utili-
zation and expenditures over a 12-month follow-up period were compared for
enrollees in restricted and unrestricted plans. RESULTS: The restricted group
(N27,595) was similar to the unrestricted group (N57,890) at baseline in terms of
the prevalence of OA/RA, serious GI events, and Charlson Comorbidity Index (CCI)
score; however, celecoxib use was significantly lower in the restricted group (11.8%
vs. 13.5%, p0.001). Total baseline medical costs were significantly higher for the
restricted group as compared to the unrestricted group ($13,641 vs. $10,456,
p0.001), whereas pharmacy costs were lower ($3,873 vs. $4,488, p0.001) for the
restricted group. No differenceswere observed between the two groups inGI event-
related costs ($643 vs. $602, p0.127). Total OA/RA related costs were significantly
higher in the restricted group than the unrestricted group ($9,432 vs. $6,642,
p0.001), which were primarily driven by inpatient costs ($6,215 vs. $3,857,
p0.001). All-cause total costs were also significantly higher in the restricted group
than in the unrestricted group ($25,428 vs. $20,793, p0.001), which were primarily
driven by the costs of inpatient and outpatient services. CONCLUSIONS: Enrollees
in plans with access restrictions to celecoxib had lower utilization of celecoxib. No
differences were observed between the groups in GI event-related costs. All-cause
and OA/RA-related costs, howver, were significantly higher among enrollees in
plans with access restrictions.
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CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH TERIPARATIDE
ADHERENCE IN MEDICARE PART D RECIPIENTS: A RETROSPECTIVE COHORT
STUDY
Hazel-Fernandez L1, Louder A2, Foster S3, Uribe C2, Burge RT3
1Competitive Health Analytics, Humana, Miramar, FL, USA, 2Competitive Health Analytics,
Humana, Louisville, KY, USA, 3Eli Lilly and Company, Inc., Indianapolis, IN, USA
OBJECTIVES: To evaluate the utilization patterns of Medicare Part D beneficiaries
newly started on teriparatide and the association of adherence with fracture out-
comes and health care utilization.METHODS: A retrospective cohort analysis was
performed using medical and pharmacy claims of 761 Humana members aged 18
and older with first prescription fills for teriparatide between January 2008 and
December 2009. Low Income Subsidy enrollees were excluded. Descriptive analy-
ses summarized baseline characteristics, healthcare use, and costs at 12 and 24
months post teriparatide initiation. Adherence was measured by Proportion of
Days Covered (PDC), categorized as high (PDC 80%), intermediate (50% PDC
80%), and low (PDC50%). Multivariate logistic regression was used to evaluate
associations of adherence with fracture rates. RESULTS: Six months before teripa-
ratide initiation, 50.7% of the cohort (386 patients) had at least 1 fracture episode,
although there was low overall comorbidity (Deyo Charlson mean 1.1). At 12
months, 21% of the cohort was highly adherent, whereas at 24 months, only 13%
was highly adherent (272 patients). More low adherent patients visited the ER or
had inpatient visits at 12 months than highly adherent patients (33% vs. 24%;
p0.05; 21% vs. 16%; NS). Total health care costs were greater at 12 months in
highly-adherent patients ($21,033 vs. $15,528; p0.05). Among thehighly adherent,
64%of costswas pharmacy-related. At 12months, only 18%of the 222 patientswith
fractures was highly adherent; this group had the highest overall fracture-related
costs, of which 89% was pharmacy-related. The regression models demonstrated
no significant association between teriparatide adherence and 12-month fracture
outcomes (OR0.81, 95% C.I. 0.53 – 1.24). CONCLUSIONS: Similar to previous stud-
ies of patients with osteoporosis, adherence to prescribed therapywas suboptimal.
Highly-adherent patients appeared to have higher overall costs due to higher phar-
macy costs, whereas patients with low adherence had higher health care utiliza-
tion.
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TUMOR NECROSIS FACTOR BLOCKER DOSE ESCALATION AMONG BIOLOGIC
NAÏVE RHEUMATOID ARTHRITIS (RA) PATIENTS IN COMMERCIAL MANAGED
CARE PLANS IN THE TWO YEARS FOLLOWING THERAPY INITIATION
Bonafede M1, Gandra SR2, Fox KM3, Wilson K1
1Thomson Reuters, Cambridge, MA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3Strategic
Healthcare Solutions, LLC, Monkton, MD, USA
OBJECTIVES: To estimate national and regional dose escalation patterns over two
years of therapy among biologic naïve RA patients initiating etanercept, adali-
mumab, or infliximab using US managed care data.METHODS: Adult (ages 18-65)
RA patients who did not use RA biologics in the prior six months, initiating etan-
ercept, adalimumab, or infliximab between July 1, 2005 and April 30, 2009 were
identified using the MarketScan® Commercial Database. National and regional
dose escalation rates were evaluated 12 and 24 months after initiation using the
Single Instance Method (one claim with an average weekly dose at least 115%,
130%, or 150% greater than the initial weekly dose) and the Two Instances Method
(two consecutive claims with an average weekly dose 130% greater than the initial
weekly dose). Dose escalation rates were compared using Fisher’s Exact tests.
RESULTS: A total of 2,747 patients met the inclusion criteria (mean age 50 years
(SD10), 74% female). More patients resided in the South (45%) than North Central
(28%), West (17%) or East (10%) US regions. More patients (44%) initiated etanercept
than adalimumab (37%) or infliximab (20%). In the first year of therapy, dose esca-
lation ranged from 0.8%-1.5% for etanercept, 10.8%-12.5% for adalimumab, and
16.4%-42.5% for infliximab using the single instance method; ranges at 24 months
were 0.8%-2.1% for etanercept, 14.3%-17.5% for adalimumab, and 26.4%-57.6% for
infliximab. At 12 and 24 and months respectively, the two instances method
showed lower dose escalation rates for etanercept (0.8%, 0.8%) than adalimumab
(8.7%, 13.3%) or infliximab (22.9%, 37.6%) at the 130% threshold (p0.001). Dose
escalation rates were consistent across US geographic regions, with etanercept
having less dose escalation than adalimumab or infliximab across all regions.
CONCLUSIONS: RA patients initiating etanercept had lower dose escalation rates
than patients initiating adalimumab or infliximab in the first and second year
following therapy initiation and across US geographic regions.
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TUMOR NECROSIS FACTOR (TNF)-BLOCKER DOSE ESCALATION AMONG
PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN A LARGE MANAGED CARE
POPULATION IN THE UNITED STATES
Fisher M1, Watson C2, Gandra SR2, Chen YW1, Fox KM3
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OBJECTIVES: To estimate dose escalation rates of etanercept, adalimumab, and
infliximab for RA patients initiating and continuing TNF-blockersMETHODS: This
retrospective analysis in the HealthCore Integrated Research Database identified
adult (18-64 years) RA patients with 1 claim for etanercept, adalimumab, or inf-
liximab between July 1, 2007 and January 31, 2010 (first claimindex). Patientswere
continuously enrolled for 6 months prior to index; patients with TNF-blocker
claims within 6 months prior to index were considered continuing therapy. Pa-
tients with other indicated conditions or contraindicated to RA biologic therapy
were excluded. Dose escalation, assessed over a 12-month period of continuous
treatment (60-day gap), was defined as: 1) 2 instances in which subsequent
doses were 130% of index dose or 2) any instances with increased number of
syringe/vial or shortened dosing interval. RESULTS: Overall, 3868 patients were
included (mean age 50.1 years; 74.4% female). Among newpatients (932 etanercept;
267 adalimumab; 292 infliximab), 4.4%, 9.0%, and 42.5% of etanercept, adalimumab,
and infliximab patients, respectively, had 2 instances of dose escalation (p0.001
for all 2-way comparisons). Most new patients (85.3% etanercept; 92.1% adali-
mumab; N/A infliximab) initiated therapy at recommended dose; of these patients,
2.3%, 12.6%, and 59.9% of etanercept, adalimumab, and infliximab patients, respec-
tively, increased by 1 syringe/vial or shortened dosing frequency. Among con-
tinuing patients (1078 etanercept; 480 adalimumab; 819 infliximab), 6.0%, 16.9%,
and 29.1% of etanercept, adalimumab, and infliximab patients, respectively, had
2 instances of dose escalation (p0.0001 for all 2-way comparisons). Most con-
tinuing patients (93.5% etanercept; 95.6% adalimumab; N/A infliximab) received
the index dose at recommended dose; of these, 4.1%, 19.6%, and 79.5% of etaner-
cept, adalimumab, and infliximab patients, respectively, increased by 1 syringe/
vial or shortened dosing frequency. CONCLUSIONS: Etanercept had lower dose
escalation rates for new and continuing patients compared with adalimumab and
infliximab in a large US managed care plan.
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COST-EFFECTIVENESS OF ALENDRONATE THERAPY FOR OSTEOPENIC
POSTMENOPAUSAL WOMEN IN JAPAN
Moriwaki K1, Komaba H2, Noto S1, Yanagisawa S3, Inoue H1, Takeshi T1, Fukagawa M2,
Takahashi HE1
1Niigata University of Health and Welfare, Niigata, Japan, 2Tokai University School of Medicine,
Isehara, Japan, 3Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Japan
OBJECTIVES: The purpose of this study was to estimate the cost-effectiveness of
alendronate therapy for osteopenic postmenopausal women in Japan.METHODS:
A Markov model with six health states (no fracture, post-vertebral fracture, post-
hip fracture, post-vertebral and hip fracture, bedridden, and death) was developed
to predict lifetime costs and quality-adjusted life years (QALYs) of five years of
alendronate therapy versus no drug treatment in postmenopausal womenwithout
fracture history. Fracture risk associated with age and bone mineral density (BMD)
was derived from epidemiologic studies in Japan. We ran the model with different
combinations of age (65 to 75), BMD (70% - 80% of the young adultmean (YAM)), and
the number of clinical risk factors (CRFs, one to three). Probabilistic sensitivity
analysiswas performed to assess parameter uncertainty.RESULTS:Themodelwas
sensitive to age, BMD, and CRFs. The incremental cost-effectiveness ratio (ICER)
was below $50,000 per QALY in the following scenarios: 1) In 70-year-old women
with BMD 70% of YAM, who had two CRFs, 2) In 75-year-old women with BMD 70%
of YAM, who had two CRFs. In 65-year-old womenwith BMD 70% of YAM, who had
three CRFs, 3) In 70-year-oldwomenwith BMD 70% and 75% of YAM,who had three
CRFs, and 4) In 75-year-old women with BMD 70% and 75% of YAM, who had three
CRFs. Applying a willingness to pay threshold of $50,000 per QALY, the probability
of being cost-effective was estimated to 2.9 %, 36.5%, and 99.2% in 70-year-old
women with BMD 70% of YAM with one CRF, two CRFs, and three CRFs,
respectively. CONCLUSIONS: Whether to treat osteopenic postmenopausal Japa-
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nese women should be determined with consideration for multiple CRFs in terms
of cost-effectiveness.
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EVALUATION OF CLINICAL PERFORMANCE AND VARIATION AMONG THREE
TYPES OF PATIENTS WITH RHEUMATOID ARTHRITIS: OPPORTUNITIES TO
RAISE QUALITY AND LOWER COSTS
Peabody J1, Strand V2, Chernoff D3, Ta H1
1QURE Healthcare, San Rafael, CA, USA, 2Stanford University, Stanford, CA, USA, 3Crescendo
Bioscience, South San Francisco, CA, USA
OBJECTIVES: To determine the quality and variability of care in rheumatoid arthri-
tis (RA). METHODS: We recruited 109 board-certified rheumatologists. Physicians
evaluated 3 common RA cases: A) mild disease activity, inadequately treated with
conventional disease modifying antirheumatic drugs (DMARDs); B) increasing dis-
ease activity, inadequately treated with conventional DMARDs; and C) stable dis-
ease activity, adequately treated with DMARDs, with a complicating co-morbidity.
Clinical performance and value (CPV) vignettes, a validated case-mix adjusted
measure of clinical practice, assessed variability and quality of care. Consented
physicians completed one online vignette for each case-type obtaining a history,
physical examination, ordering tests and determining treatments. Criteria for eval-
uating clinical decisions were based on ACR guidelines, published evidence and
expert panels. Vignette scores are reported as percentages of total criteria correct
overall and by domain, (e.g., treatment prescribed). RESULTS: The mean quality
score for all simulated cases (n327 cases) was 61.3%%. Mean scores for history
were 62.8%; physical examination: 55.8%; laboratory testing and imaging: 61.1%;
disease activity assessment: 52.6% and treatment: 66.9%. Ordering unnecessary
tests was most common: rheumatologists ordered 1.8 additional laboratory and 1
additional imaging test. Among the 3 case types, lowest quality and most clinical
variability occurred in the case with the co-morbidity (Case C), associated with
unnecessary testing and inappropriate use of biologic and/or combination
DMARDs. Variability was also found in Cases A and B: 3 of 10 and 2 of 10 rheuma-
tologists, respectively, used combination and/or biologic DMARDs unnecessarily.
CONCLUSIONS: Improving quality and lowering cost is a strategic focus of payers
and providers. Using CPV vignettes, we found a wide range of variation in RA
practice, which resulted in unnecessary testing, repetition of potentially expensive
imaging studies and varying use of DMARDs. This variability indicates there are
opportunities to improve quality of care and lower costs.
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A SYSTEMATIC LITERATURE REVIEW OF ECONOMIC STUDIES AND A COST
ANALYSIS RELATED TO EPIDURAL STEROID INJECTIONS IN THE ELDERLY
Bresnahan B1, Rundell S2, Friedly J2, Jarvik J1, Sullivan SD2
1University of Washington, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA
OBJECTIVES: To appraise existing economic evaluations of epidural steroid injec-
tions (ESIs) for lumbar spinal stenosis and to estimate Medicare-based reimbursed
amounts. METHODS: We searched PubMed through June 2011 for low back pain,
spinal stenosis or sciatica, and ESI and included observational studies with cost
outcomes. We performed a supplementary descriptive analysis of Medicare reim-
bursed amounts associated with ESI performed at a single institution in 2010.
RESULTS: Our literature search indicated that rates of lumbar ESI increased 271%
from 1994 to 2001 in Medicare beneficiaries 65 years of age with professional
charges per injection nearly doubling ($115 to $227) during this time period. A
second study found the rate of lumbar epidurals was 67% higher in 2006 versus
2002 in Medicare beneficiaries of any age, and allowed charges of all spine epidural
increased from $336 to $395. Our single-institution estimation sample included 279
patients receiving one (n179), two (N93), three (N30), or four (N2) ESIs. We
estimated mean total Medicare reimbursement per outpatient ESI episode proce-
dure to be $635 in 2010 (technical reimbursement and estimated professional pay-
ment). The associated reimbursement estimates were $1239 and $1834 for those
receiving 2 and 3 ESI episodes, respectively. CONCLUSIONS: There are few studies
investigating the economic impact of ESI procedures for lumbar spinal stenosis in
the elderly, or providing estimates of technical and professional reimbursement
amounts. Our single-institution estimate suggests thatMedicare-based reimburse-
ment is greater than $600 per ESI (technical and professional). More information on
utilization, costs, and cost-effectiveness of ESI in treating lumbar spinal stenosis
are needed.
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DEVELOPING AND IMPLEMENTING PATIENT-RESOURCE USE DIARIES FOR A
CLINICAL TRIAL ASSESSING SPINAL STENOSIS INTERVENTIONS IN THE
ELDERLY
Bresnahan BW, Rundell S, Comstock B, Sullivan SD, Jarvik JG, Nguyen H, Bauer Z,
Friedly J
University of Washington, Seattle, WA, USA
OBJECTIVES: To develop and implement patient-reported resource use question-
naires for assessing utilization and costs in elderly patients with lumbar spinal
stenosis (SS), as part of an epidural steroid injection randomized clinical trial (RCT)
in multiple integrated health systems. METHODS: We developed patient-com-
pleted diaries for a RCT in an elderly populationwith SS to capturemedication use,
time, and costs incurred by patients. Diary sections included: prescription opioid
medications, non-opioid analgesics and over-the-counter (OTC) products, thera-
peutic services, time spent for SS care, and products purchased for back pain. We
summarized demographics and commonly-reported opioid medications for cur-
rently-enrolled subjects. RESULTS:We implemented resource use diaries in a RCT
during baseline to week 3, weeks 4-6, weeks 24-26, and weeks 50-52. Overall, the
diaries capture 12 weeks of data, distributed at key time points, during 12 months.
The prescription opioid section and OTC section collect dose and daily medication
use intensity. Later sections capture weekly visits, time, and purchases for back
pain. We integrated the patient questionnaires into our overall electronic data
management system, including prompts for sites to send participants diaries, col-
lect diaries and enter the data on our RedCap™ electronic data capture system. To
date, 100 RCT participants completed baseline diaries. The mean age was 69.6
years, 59% were females, and approximately 29% were from minority groups. The
most commonly reported opioid medications were hydrocodone-acetaminophen
and acetaminophen-codeine.CONCLUSIONS: It is important to capture the patient
perspective in RCTs, particularly those with complex interactions among pain,
functioning, medication use and economic endpoints. Electronic medical records
are powerful tools to assess clinical and economic resource use, but still have
limitations on collecting what patients spend and do to manage their pain condi-
tion. Logistical challenges and patient burden of completing questionnaires must
be weighed against a more comprehensive economic evaluation andmanagement
of a high-priority condition.
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ANNUAL GOLIMUMAB UTILIZATION AND COSTS FOR PSORIATIC ARTHRITIS
PATIENTS ENROLLED IN MANAGED CARE PLANS
Carter C1, Smith D2, Tandon N1
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2IMS Health Consulting Group, Watertown,
MA, USA
OBJECTIVES: To calculate expected mean annual golimumab costs based on ob-
served one-year dosing patterns within a managed care population of psoriatic
arthritis (PsA) patients.METHODS: IMS LifeLink™Health Plan Claims databasewas
utilized to identify patients with: index golimumab claim (4/24/2009-01/06/2010);
age 18 years at index; 1 PsA diagnosis code (696.0); and 12/ 12 months pre-/
post-index continuous enrollment. Biologic experiencewas defined as1medical/
pharmacy claims for another biologic 12 months prior to the first golimumab pre-
scription. Golimumab utilization was reported as the proportion of patients and
prescriptions at the recommended 50 mg dose, and prescription intervals, for the
12 month post-index period. Annual costs were modeled using the golimumab
United States wholesale acquisition cost (effective 7/5/2011) of $1,941.65 per 50mg.
RESULTS: 127 PsA patients receiving golimumab (n914 prescriptions) were iden-
tified; 59.8% were female; meanSD age was 4910 years. The majority (78.7%) of
patients had pre-index biologic experience; 73.0% experienced 1 unique biologic,
24.0% experienced 2 unique biologics, and 3.0% experienced 3 unique biologics at
some time point before golimumab. A 50 mg golimumab dose was dispensed in
95.3% of all PsA patients upon initiation and 96.6% of all prescriptions. The dose at
each of the first 12 prescription fills was 50mg for 95.2%-97.9% of patients. A 50mg
dose was dispensed upon initiation in 94.0% and 100.0% of biologic-experienced
and non-biologic-experienced PsA patients, respectively. Overall meanSD inter-
val between prescriptions was 3214 days; median was 30 days. Based upon ob-
served prescription intervals, a mean annual acquisition cost of $22,135 would be
realized. CONCLUSIONS: The majority of PsA patients receiving golimumab was
biologic-experienced and received a 50mg dose on amonthly basis with no appar-
ent increased dose requirement. Estimated average annual per patient golimumab
cost in a managed care PsA population would be $22,135.
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TWO-YEAR DIRECT HEALTH CARE COST BURDEN OF PSORIATIC ARTHRITIS TO
MANAGED CARE: A RETROSPECTIVE CASE STUDY OF GOLIMUMAB PATIENTS
Carter C1, Smith D2, Tandon N1
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MA, USA
OBJECTIVES: To describe the 2-year disease-related direct healthcare costs of pso-
riatic arthritis (PsA) patients, in managed care, prior to initiating golimumab
(baseline).METHODS: The IMS LifeLink™Health Plan Claims databasewas utilized
to identify patients who had/were: index golimumab pharmacy claim started April
24, 2009-June 30, 2010; aged18 years at index;1 PsA ICD-9 diagnosis code (696.0);
and 24 months pre- and  6 months post-index continuous enrollment. Total
disease-related direct healthcare costs included medical (inpatient, outpatient)
and pharmacy (biologic and non-biologic treatment) costs. Disease-related allow-
able healthcare costswere calculated fromoutpatient and inpatient claimswith an
ICD-9 diagnosis code for PsA (696.0) or rheumatoid arthritis (RA-714.xx). Pharmacy
costs were calculated from allowed costs for biologic and non-biologic treatments
used in PsA, RA, or psoriasis. RESULTS: A total of 211 golimumab patients with PsA
(n180 with pre-index biologic experience) were analyzed; meanSD age was
5010; 61.1% female. Concomitant diagnosis codes for RA or psoriasis were found
in 39.8% and 51.2% of all PsA patients, respectively. Total meanSD pre-index
PsA-related costs were $3,569$9,231. Mean PsA-related outpatient medical costs
represented 92.0% of total PsA-related costs. Among the 114 patients with a comor-
bid RA diagnosis code, overall mean pre-index total RA-related costs were $2186.
Mean disease-related pharmacy costs for the 2-year period prior to golimumab
totaled $28,041. Based on the disease-related outpatient, inpatient, and pharmacy
costs, the 2-year direct mean per patient disease-related health care costs in PsA
was $32,791. CONCLUSIONS: In this study, annual managed care per patient direct
PsA healthcare costs were $16,369. This new economic burden of illness estimate
may further aid decisionmakers in assessing the cost-effectiveness and budgetary
impact of PsA therapies, including biologics. This estimate, however, should be
considered in the context of incremental improvements in clinical outcomes asso-
ciated with biologic treatments compared with older PsA therapies.
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